Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation

• Status: Not yet recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Airflow limitation is common exist in idiopathic bronchiectasis patients. However, there are few evidence on the treatment of bronchodilator in bronchiectasis with airflow limitation. The efficacy and safety of dual bronchodilator in idiopathic bronchiectasis with airflow limitation are still unclear. Thus, the investigators conduct a multicenter, open-label randomized controlled trial to investigate the efficacy and safety of dual bronchodilator in idiopathic bronchiectasis with airflow limitation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
• Treatments: Bronchodilator Agents

Criteria

Inclusion Criteria:

• Idiopathic bronchiectasis with FEV1/FVC < 70%

Exclusion Criteria:

• With Asthma

• α-1 antitrypsin deficiency

• Turculosis

• Lung cancer

• Sarcoidosis

• Idiopathic pulmonary fibrosis

• Primary pulmonary hypertension

• Uncontrolled sleep apnea

• Bronchiectasis accepted long-term low dose macrolides

• Pulmonary surgery within 6 months

• Lower respiratory tract infections require antibiotic treatment in 6 weeks

• Upper respiratory tract infection did not recover for at least 7 days

• With Glaucoma or severe prostate hyperplasia that can not use Indacaterol

• Patients allergic to experimental drugs

• Women pregnant, breast-feeding or who planned a pregnancy during the study